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Glossary of Abbreviations 
 
PCI   Percutaneous Coronary Intervention 
IVUS   IntraVascular UltraSound 
FFR   Fractional Flow Reserve 
MLD   Minimum Lumen Diameter 
CSA   Cross-Sectional Area 
QCA   Quantitative Coronary Angiography 
PTCA   Percutaneous Transluminal Coronary Angioplasty 
MUSIC  Multicenter Ultrasound Stenting In Coronaries study 
BENESTENT  BElgian NEtherlands STENT study 
LAD   Left Anterior Descending coronary artery 
LCX   Left Circumflex coronary artery 
RCA   Right Coronary Artery 
SAM   Surface-Adherent Monocytes 
TIM   Tissue-Infiltrating Monocytes 
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1. INTRODUCTION 
1.2 Coronary Luminology 
 
For more than 40 years, coronary angiography remained to be the “gold standard” for 
describing coronary anatomy.1 In 1957, coronary atherosclerotic disease was first 
directly visualized when Sones performed the first selective coronary angiogram.2 It 
marked the start of a new field of cardiovascular medicine – Interventional Cardiology. 
It was the beginning of a new paradigm, “Coronary Luminology”, where cardiologist 
relied heavily on coronary angiography to guide them in their clinical practice. 
Unfortunately, the coronary silhouette was a relatively poor representation of the 
coronary anatomy which was a limited standard reference to guide them for 
revascularization. Angiography underestimated the severity of coronary lesion in 
relation to post-mortem histological findings. Later, the physiological status of the 
lesion was found to be poorly correlated with angiographic stenoses.3-10 
 
Therefore, visual interpretation showed major discrepancies among estimations of 
lesion severity. Limitations of angiography had lead to inventions of better imaging of 
the coronary artery lumen. Intravascular ultrasonography demonstrated coronary lesions 
to be often complex, with markedly distorted or eccentric luminal shapes.  
 
Then, the phenomenon of coronary “remodelling “ was first described by Glagov in 
1987.11 The remodelling process was an outward displacement of the external vessel 
wall overlying the atheroma. This could be clearly visualized by intravascular 
ultrasound. 
 
Eventually, the quantitative coronary angiography was first introduced by Brown in the 
late 1970’s which was intended to replace the “eyeballing” evaluation of a coronary 
stenosis. 12 But actually, it still possessed all the shortcomings of  the conventional 
angiogram. 
 
Before Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial was 
published in 1987, demonstrating that angioplasty was unnecessary and potentially 
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deleterious after successful thrombolysis,13 the practice of “oculo-stenotic” reflex was 
common denoting the irresistible temptation among invasive cardiologists to perform 
angioplasty on any significant residual stenosis after thrombolysis of acute myocardial 
infarction. 
 
1.2 Coronary Stenting 
 
Thereafter, the concept, “bigger is better”, was introduced.14 This paradigm referred to 
the theory that a larger luminogram will translate into better clinical outcomes.15 
Afterwards, stents flourished as stimulated by greater improvement in the coronary 
lumen dimensions in acute and late angiographic results.16-18 The first clinical report on 
coronary stenting by Sigwart indicated that metal stents produced too many thrombotic 
complications on cohort patient follow-up. But, they used only rudimentary 
antithrombotic medical regimen on their subjects.19 Research was even directed towards 
optimization of stent deployment through high-pressure inflations and/ or ultrasound 
guidance. 
 
1.3 High Pressure Strategy versus Arterial Injury 
 
Colombo demonstrated that most stents deployed at 6-8 atmospheres were grossly 
unexpanded, asymmetrically deployed, and not apposed to the vessel wall.20-22 
Incomplete stent deployment led to mechanical flow disturbance. Together with 
thrombogenicity associated with arterial wall injury, inherent stent thrombogenicity 
primarily resulted into stent thrombosis.23-27 
Nakamura showed that despite excellent angiographic results , most of the stents 
deployed at low pressure remained suboptimally expanded by IVUS criteria. But, after 
using high-pressure post-dilatation, stent CSA improved. Even so, the final stent CSA 
rarely exceeded 60-80% of the nominal balloon CSA.20 
 
Colombo promoted high pressure stent implantation which was later recommended in 
the American College of Cardiology Expert Consensus Document on Coronary Artery 
Stents.28 
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High pressure inflation had been recommended in the primary percutaneous 
intervention of acute myocardial infarction.( ≥16 atm)29-31 
But, higher pressure strategy was equated with greater vessel wall injury. This initiated 
excessive tissue growth repair which translated into intimal hyperplasia and, 
consequently restenosis.32-41 Several studies showed its detrimental effects on the stent 
and vessel. Aside from resulting in distorted stent geometry, medial injury with 
exposition of adventitia and lipid core penetration by struts resulted in increased 
inflammation.42-45 
Farb described that after coronary stenting, early thrombus formation and acute 
inflammation occurred and followed by neointimal growth.46 Thus,  Farb challenged the 
adage, “the bigger the vessel, the better the outcome.”47 He was more inclined to 
preaching, “the more you gain, the more you lose.”44 
Investigators proposed an injury score for the arterial wall as a result of high pressure 
stent implantation on coronary lesions with correlation to higher risk of restenosis.  In 
experimental animal studies, the extent of neointimal proliferation was associated with 
arterial wall damage. A lesion treated with more than 16 atmospheres and a balloon to 
artery ratio of more than 1.1 translated into greater angiographic late loss and lower 
MLD at follow-up.17,18,48,49 
1.4 Oversizing of Stent Strategy 
 
Johansson utilized the strategy of oversized stents to achieve optimum stent deployment 
but still with high inflation pressures. These improved luminal gain without having 
complications during routine stenting procedure. It was even associated with low target 
vessel revascularization.41 
So, aside from high pressure stent implantation, interventionists tend to be more 
aggressive by also using oversized balloons. Goldberg found greater lumen dimensions 
through this approach.50 
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The CLOUT Pilot Trial declared the safe use of oversized balloons which resulted to 
significant luminal dimensions without increasing risks for dissection and ischemic 
complications.32 
 
1.5 Mathemathical Modelling: Arterial Injury  
 
Rogers used mathematical modelling through finite element analysis to understand the 
factors  involved in vascular injury during stent implantation that lead to restenosis. 
Modifying the influence of these mechanical factors by optimizing stent design and 
stent-placement protocols could limit vascular injury and subsequently reduce 
restenosis. Results showed that higher inflation pressures, wider stent-strut openings, 
and more compliant balloon materials contributed largely to bigger surface-contact area 
and contact stresses between stent struts.51 
Stent-induced arterial injury was previously considered to be limited to sites of stent 
struts and deep wall laceration meant greater vascular response.44,52-54 During stent 
expansion, endothelial regions removed from stent struts themselves exhibit also 
vascular injury.55 The balloon-artery surface stress or contact area in between stent 
struts with the balloon and arterial wall played a major role in vascular injury as 
modified by stent strut configuration, interstrut distance, placement pressure, balloon 
materials, and balloon compliance.51 
Finite element analysis revealed that maximum balloon-artery surface-contact force 
grew in a nonlinear fashion as balloon pressure rose. A rapid increment in predicted 
maximum arterial-surface force between 12 and 18 atmospheres. Beyond such 
pressures, a plateau with the force formed. These could be applied in clinical practice 
wherein higher post-dilatation pressures were correlated with greater restenosis.21,39 
1.6 Restenosis: The Most Recent Uncontrollable Dilemma 
 
Restenosis was creating a terrible dilemma among interventionists who are currently 
making use of pharmacological armamentarium and newly-designed devices to prevent 
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revascularization. Animal studies had already documented this occurrence and was best 
observed in clinical investigations with the intravascular ultrasound.35,48,56,57 
 
A clear understanding of the process of vascular response to stenting should be obtained  
to solve the problem of restenosis. Restenosis due to balloon angioplasty was caused by 
smooth muscle cell-rich intimal hyperplasia accompanied by arterial size and geometric 
remodelling changes. The inflated balloon came in contact with the normal or 
atherosclerotic wall surfaces, thus abrading the arterial endothelium and forming 
dissection planes within plaque burdens. Since the thromboresistant endothelial layer 
was removed, deeper wall structures were exposed to blood flow and particles. Thus, 
thrombosis ensued. This was just the starting phase which lead to a sequence of events 
including smooth muscle cell migration and proliferation, and the resulting intimal 
hyperplasia.58 
The vascular response to stenting was a more extensive and prolonged course. Animal 
studies showed that the intimal proliferation from stenting was four times greater than 
balloon inflation.59-61 Even in clinical studies, the late lumen loss was greater than 
balloon angioplasty.62-65 The first phase of thrombosis occurred within the first three 
days after stent implantation. Platelets and fibrin were deposited on subendothelial 
connective tissues. Focal mural thrombus deposition occurred but did not encroach the 
lumen significantly. The reaction depended on how deeply the struts penetrated the 
wall. Greater arterial injury entailed greater thrombotic response. So, minimal arterial 
injury could virtually spare the involved vessel.44,56,66 The second phase of vascular 
repair started at the formed thrombus in between the struts. Activated platelets released 
cytokines and adhesion molecules. These were the mononuclear and polymorphonuclear 
leukocytes that adhered to the stretched internal elastic membrane. They promoted 
inflammatory cell recruitment and migration across the endothelium into the arterial 
wall. The surface-adherent leukocytes would eventually be the determinant for the rate 
of proliferation within the lesion.66 These decreased as the tissue-infiltrating 
macrophages increased which occurred 3-7 days after stent implantation. These cells 
migrated to the developing neointima to become multinucleated giant cells around struts 
and also to the cellular intima distant from the struts. The third phase was the intimal 
cell proliferation wherein inflammatory cells from the vessel surface penetrated to the 
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neointima seven days after stent implantation. Both smooth muscle cells and monocytes 
had proliferative potentials contributing to the metabolic and architectural framework of 
the extracellular matrix. The fourth phase involved overall deformation of the arterial 
wall. Elastic recoil was part of the early response. Then, geometric remodelling 
occurred by collagen deposition and fibrosis causing shrinkage of artery. The arterial 
wall squeezed through the stent strut interstices.67 Through increased collagen 
deposition, marked destruction of elastin, and persistent inflammation, the artery 
opposed the strain forced by the stent struts. The healing process was completed by re-
endothelialization occurring weeks to months. This vasculoproliferative process 
following stent implantation was observed both in restenosis animal models and in 
human atherosclerotic lesions.45,59,68-70Refer to Figure 1. 
 
Figure 1. The graphs described the different stages 
of vascular repair after stent-induced arterial injury. 
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1.7 Statement of the Problem 
 
New generation stents were eventually manufactured to solve the current problem of 
restenosis. Since restenosis was caused by arterial injury aggravated by high pressure 
balloon inflation, newly designed stents were continuously developed to fully expand 
with the use only of nominal or low pressure minimizing vessel trauma. Optimal stent 
deployment could only be properly monitored by QCA and IVUS. This study utilized a 
newly designed tubular stainless steel stent, the EXPRESS™ Coronary Stent System 
which was developed to adopt low pressure as its optimal deployment pressure. 
Therefore, the null hypothesis stated that there was no significant difference between 
the normal pressure stent implantation balloon inflation parameters and the high 
pressure postdilatation balloon inflation parameters in terms of optimal stent 
deployment criteria measured through QCA and IVUS making use of the new 
generation stent, the EXPRESS™ Coronary Stent System. 
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2. MATERIALS: 
2.1 EXPRESSTM Coronary Stent System 
 
This device consists of a balloon-expandable stent pre-mounted on a high-pressure 
delivery catheter. The stent is laser cut from 316L stainless steel tubing patterned after a 
specific geometric design, the TANDEM ARCHITECTURE TM stent design. In this study, the 
device was intended to provide permanent structural support  and to increase arterial 
luminal diameters in a atherosclerotic lesion of  native coronary arteries by stent 
implantation.71,72 
 
2.1.1 TANDEM ARCHITECTURE TM Stent Design: 
This stent design combines two important composite elements responsible for its first 
class delivery to the target lesion. Firstly, the MicroTM Elements are short, narrow radial 
components which contribute to its outstanding flexibility and excellent conformability 
in relation to the natural contour of the coronary artery. Secondly, the MacroTM Elements 
are composed of long, wide radial components  to enhance its radiopacity and contribute 
to stent diameter for larger open cell area.71 
 
2.1.2 Other Features: 
 
This coronary stent system offers a lot of features to promote its first class delivery to 
the periphery of the coronary tree. Its Laser Bonded TrakTipTM provides precise, smooth 
transitions for enhanced crossability through difficult angles of atherosclerotic vessels.  
Crimp 360TM offers excellent stent-to-balloon securement to prevent displacement of the 
stent during its delivery to the target lesion. Controlled dilatation of the DYNALEAPTM 
balloon promotes precise stent deployment with minimal balloon overhang (no dogbone 
effect) and predictable balloon inflatation.71 
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3. METHODOLOGY: 
3.1  Patients 
3.1.1 Inclusion Criteria 
 
Patients were decided to be included in the study only after the diagnostic coronary 
angiography was performed. 
 
They were recruited in the study when they fulfilled the following criteria: 
1. He presented with chronic stable angina as chief complaint. 
2. His coronary angiography showed a significant de novo lesion in a native vessel 
or significant de novo lesions in a native vessel or vessels 
 
A stenotic lesion was defined to be significant based on the following conditions: 
1. when the stenosis diameter was more than 70% as compared to its reference 
diameter. 
2. when the stenosis diameter was between 40 and 70% as compared to its 
reference diameter which was called intermediate lesion, then further evaluation 
by fractional flow reserve was done. When the fractional flow reserve was less 
than 0.75, then it was classified as significant. 
 
When a lesion was classified to be significant, then percutaneous coronary intervention 
was performed. 
 
3.1.2 Exclusion Criteria 
 
Patients are excluded from the study when they have the following characteristics: 
1. He was admitted as an emergency case. 
2. The stenotic lesion was in a vein graft. 
 
3.2 PCI Protocol 
 
Pre-dilatations were performed once or several times at the discretion of the operator. 
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The stent was implanted at nominal pressure of nine atmospheres as specified by the 
manufacturer. A repeat coronary angiography and intravascular ultrasound were 
performed afterwards. When the operator perceived the stent deployment to be optimal 
by eyeballing based on both angiography and IVUS, then PCI has ended. The stent 
group was categorized as Group A. 
 
On the other hand, when after implanting the stent at nominal pressure, the repeat 
angiography showed incomplete stent expansion, the operator proceeded directly to 
high pressure post-dilatation without performing intravascular ultrasound. The stent 
group was categorized as Group B. 
 
Moreover, when the implanted stent at nominal pressure was perceived to be optimal by 
eye-balling based on repeat angiography, then IVUS was performed. When the stent 
was perceived to be optimal by eyeballing based on IVUS, then PCI has ended. The 
stent was categorized as Group A. 
 
But, when the stent was perceived to be unsuccessfully deployed by eyeballing based on 
IVUS, the operator proceeds to high pressure post-dilatation. The stent was categorized 
as Group B. 
 
Post-dilatations were performed once or several times at the discretion of the operator. 
See Figure 2. 
 
3.3 Patient’s Informed Consent 
The study was conducted according to the Declaration of Helsinki on Biomedical 
Research Involving Human Subjects.73 The study was only considered whenever the 
operator has chosen the EXPRESS™ Coronary Stent System to be deployed for the target 
lesion as determined from the diagnostic coronary angiography. Thereafter, the patient 
received all the necessary information before the written informed consent was 
obtained. 
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3.4 Investigator’s Disclosure 
 
This study was conducted with no vested interest for the manufacturer nor for the 
operators and investigator. No sponsoring was granted by the company in favor of the 
investigator. This study was submitted for poster presentation at the Annual Meeting of 
the German Cardiac Society, the European Society of Cardiology and the American 
College of Cardiology. 
 
Figure 2. Algorithm of Methodology 
 
1. Chronic Stable Angina 
2. Angiography with de novo 
lesion in a native vessel
Predilatation 
on discretion 
Angiographic 
“eyeballing” 
of stenosis
<40%
40-75% 
>75% 
Medical 
ManagementF F R
>75% 
≤75%
PCI
Nominal Pressure 
Stent Implantation 
Angiography 
“eyeballing” of
deployment 
OK
IVUS OK
poor 
poor 
A
High Pressure Postdilatation 
Angiographic eyeballing 
after postdilatation OK IVUS OK
B
poor 
ASA 100mg/day 
Clopidogrel 75mg/day
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3.5 Optimum Stent Deployment Criteria 
 
The MUSIC criteria was used as reference for optimal stent expansion: 
1. The stent must be completely apposed over the entire length against the vessel 
wall. 
2. The minimum in-stent CSA must be ≥90% of the average reference CSA or 
≥100% of the minimum reference CSA. 
 
In case the minimum in-stent CSA reached ≥9.0mm2,
• The minimum in-stent CSA must be ≥80% of the average reference CSA or 
≥90% of the minimum reference CSA. 
If the regions adjacent to the stent showed a dissection or evidence of thrombus, the 
operator was allowed to proceed based on his own clinical judgement, that was, to use 
other balloons or to insert  additional stents of any type and size. 
 
The patients with inability to evaluate the proximal or distal reference segments due to 
side branching were still included in the study. 
 
3.6 Medications 
 
3.6.1 Pre-medications: 
 
Patients should be taking ASA at a minimum dose of 100mg per day or Clopidogrel 
75mg per day. Otherwise, they were required to take Clopidogrel 75mg/tab 4 tablets as 
loading dose. 
 
3.6.2 Anti-coagulation for PCI: 
 
5,000-10,000 units of unfractionated heparin as bolus were administered intravenously 
after insertion of the introducer sheaths. Further boluses were given during intervention 
to maintain the Activated Clotting Time (ACT) to more than 250 seconds. 
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Intravenous unfractionated heparin boluses was no longer given after the procedure. The 
introducer sheaths were removed when the ACT was already below 160 seconds. 
 
3.7 Diagnostic Modalities 
3.7.1 Coronary Angiography Procedure 
 
The Ludwig Maximilian University Hospital-Innenstadt in Munich was using 
INTEGRIS Allura 9 Biplane system for their catheterization laboratory. It was a biplane 
system for diagnostic, vascular and interventional procedures with frontal Poly 
DIAGNOST G-arm stand, lateral C-arc and digital imaging. Cannulation of the ostium 
with the appropriate diagnostic or guiding catheter was skillfully executed after sterile 
puncture of the femoral artery at the groin. Selective coronary angiography of the artery 
of interest was performed with injection of less than 10 cc of contrast medium. The 
coronary lesions were best visualized with proper angle projections preventing 
foreshortening followed by a short period of digital recording. 
 
3.7.2 Quantitative Coronary Angiography Analysis 
 
The new version of Cardiovascular Angiography Analysis System (CAAS II) was used 
to perform quantitative analysis. It was a user-friendly software allowing easy and fast 
analysis of cardiovascular angiographic images. These images were already digitized in 
the catheterization laboratory produced as Digital Imaging and Communications in 
Medicine, Version 3.0 (DICOM-3) image format standard and stored on the Compact 
Disc-Recordable (CD-R) as the exchange medium. The DICOM-3 standard prescribed 
that images be stored in a 512 x 512 and 1024 x 1024 bits format with 8 and 10 bits of 
density levels and that raw, that was, the uncompressed and unenhanced, data be made 
available on the DICOM-disc. Boundaries of a selected coronary segment are detected 
automatically. The absolute diameter (in millimeter) of the stenosis was determined 
using the guiding catheter as a scaling device. All study frames selected for analysis 
were end-diastolic to minimize motion artifacts, and arterial segments were measured 
between the same identifiable branch points. Refer to Figure 3. 
 
Page  14
Ludwig-Maximilians-Universität 
Figure 3. A sample case of QCA analysis software application wherein 
MLD, % diameter stenosis and the reference diameter were 
automatically measured after arranging the position of the lesion 
borders (inner lines) and reference points (outer lines). Both pre-PTCA and 
post-stent angiographic images were evaluated showing the automatic 
boundary detection. But, only the pre-PTCA results were shown. 
 
3.7.3 Intravascular Ultrasound Examination Procedure 
 
IVUS studies were performed with a mechanical 30 MHz imaging system. The catheter 
of the CVIS Insight system ( Sunnyvale, CA, USA ) housed an ultrasound transducer 
and a rotating mirror.  All IVUS studies were performed after 100 to 200 µg of 
intracoronary nitroglycerine were administered. Care was taken to adjust the settings for 
time - gain compensation to yield optimal image quality. The ultrasound catheter was 
advanced distally over a guidewire >10 mm beyond the lesion, and an imaging run was 
performed to a point 10 mm proximal to the lesion with motorized transducer pullback 
at 0.5 mm/s. Data were recorded onto a high-resolution super-VHS videotape for offline 
analysis. Cross-sections of insufficient image quality to determine lumen or vessel area 
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and cross-sections showing a calcified lesion of >180 degrees were excluded from 
quantitative analysis. 
 
3.7.4 Intravascular Ultrasound Planimetry Measurement 
 
Quantitative IVUS analysis was performed by computerized planimetry (TapeMeasure, 
Indec Systems). Post-interventional stent cross-sectional areas were measured almost at 
1 mm interval. The proximal and distal reference segments, the least diseased portion,  
were also sliced at almost 1 mm interval within 10 mm from both ends of the stent 
before any major side branch.. The stent struts, intima or luminal border, and external 
elastic membrane or media-adventitia border were distinctly identified and marked to 
measure the following cross-sectional areas. Refer to Figure 4 and 5. 
 
1. Stent (luminal) area = area within the stent struts 
2. Luminal area = area within the intima measured at the proximal and distal 
reference segments 
3. Vessel area = area within the external elastic membrane 
4. Lumen symmetry = ratio between minimum stent luminal diameter and 
maximum stent luminal diameter 
 
Lesion calcification was also quantified using maximum arc of calcium in degrees as 
measure of severity. Refer to Figure 5. 
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Figure 4. An IVUS image sliced within the stent segment 
showing fully expanded stent with good lumen symmetry 
and stent apposition. 
 
Figure 5. An IVUS image sliced at the reference segment 
showing irregularly shaped lumen with rough intimal border. 
Calcified plaque was evident due to acoustic shadowing. 
IVUS
IVUS
Stent Area
Media
Stent Struts
Media-Adventitia Border
Lumen 
Area
Calcified Plaque
Intima
Acoustic 
Shadow
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Figure 6. Demonstration of failure of stent 
deployment due to (A) poor apposition of stent 
to vessel wall and (B) underexpanded stent. 
 
3.7.5 Myocardial Fractional Flow Reserve 
 
Fractional flow reserve (FFR), defined as the ratio of maximum flow in the presence of 
a stenosis to normal maximum flow, was a lesion-specific index of stenosis severity that 
can be calculated by simultaneous measurement of mean arterial (Pa), and distal (Pd)
coronary pressures during pharmacological vasodilation. 
 
A 6-French guiding catheter was introduced into one femoral artery, and was advanced 
into the ostium of the coronary artery. Pa was monitored by this guiding catheter. 
Nitroglycerin 0.5 mg sublingual spray was administered and repeated every 30 minutes. 
Angiograms of the target vessel were then obtained as usual. 
 
To measure Pd, an 0.018-in fiber-optic high-fidelity pressure-monitoring wire was used 
(Pressure-guidewire, Radi Medical Systems, Uppsala, Sweden). After calibration, this 
fiber-optic wire was introduced into the guiding catheter and advanced to its tip. At that 
point, equality of pressures registered by the guiding catheter and the fiber-optic wire 
was verified. 
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The wire was then advanced into the coronary artery and positioned across the stenosis. 
Pa, and Pd, were monitored continuously during the procedure. After the pressures was 
stabilized, maximum coronary hyperemia was obtained by intravenous adenosine (140 
microgram/kg/min) infused through the side arm of the venous sheath. The further 
decrease of distal coronary pressure was associated with maximum hyperemia. From the 
simultaneous recording of Pa, and Pd at steady-state maximum hyperemia, FFRmyo before 
PTCA was automatically calculated and displayed in the RADIAnalyzerTM interface. 
Then manual pullback was done gradually to pinpoint the real culprit lesion. See Figure 
7. 
 
Figure 7. The FFR was calculated as a ratio of the pressure 
distal to the stenotic lesion or pressure of the distal part 
of the coronary artery as the numerator(Pd) and the aortic 
pressure recorded at the ostium as the denominator(Pa). 74 
 
The RADIAnalyzerTM interface was composed of a graphic display that presents real-
time curves and numerical values. Thus, it provided hemodynamic information for use 
in the diagnostic and treatment of coronary artery disease. 
 
After adenosine infusion was stopped, an adequate balloon catheter with an 0.018-in 
central lumen was advanced over the fiber-optic wire, and then angioplasty was 
performed. During the balloon inflations, Pa, and Pd (then called Pw), were also 
continuously recorded. After a satisfactory angiographic result was obtained, adenosine 
infusion was started again for post-PTCA recording of Pa, and Pd, at maximum 
Pa
PdPd
Pa
=1.00
Normal value
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hyperemia. This allowed calculation of the post-PTCA value of FFR. Finally, the fiber-
optic wire was withdrawn into the guiding catheter, and equality of both pressures was 
rechecked for drift. 
 
Figure 8. This was the RadiAnalyzer interface showing the 
FFR, mean distal pressure, and mean aortic pressure. 
Other features of the apparatus such as the coronary 
flow reserve, temperature change, and transit time were 
shown but were not necessary for this study. 
 
3.8 Statistics: 
 
Due to the unequal and small sample sizes of two independent groups in the study, the 
necessity to check normality of distribution by Kolmogorov-Smirnov test and equality 
of variances by Levene test were always under consideration. After fulfilling the 
aforementioned required conditions, the Student’s t-test for unpaired sample groups was 
utilized to detect differences of mean with standard deviations between groups with 
numerical and ordinal variables. The clinical features such as age of the patients, body 
mass index, serum creatinine level; angiographic measures such as minimum lumen 
diameter, percent diameter stenosis, reference diameter, and lesion length; and lastly, 
the sonographic parameters such as minimum and average cross-sectional areas of 
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reference and stented segments were all treated accordingly observing all required 
assumptions. 
 
The chi square test was appropriate to compare proportions of nominal variables of 
independent groups with rather not so small frequencies. Most of the clinical profile and 
optimum deployment criteria by IVUS and QCA were categorical variables. 
 
The Student’s t-test for paired groups was used to compare means between stent 
implantation and post-dilatation cross-sectional area parameters of Group B. 
 
Pearson’s correlation coefficient r expressed the association of severity of calcification 
of lesions with the minimum and average cross-sectional area of the stent region. 
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4. RESULTS: 
 
Between September 2002 and February 2004, 33 patients were enrolled in the 
Department of Cardiology in the University Hospital-Innenstadt of Munich.  
 
4.1 Stent Dropouts 
 
Out of the 47 stents used for the study, seven were excluded because of technical 
reasons. The seven excluded stents should have been included in Group B. Two had no 
angiographic film after nominal pressure stent deployment. Two had only one IVUS 
imaging. One was directly deployed with high pressure inflation.  One IVUS 
examination was erased. Another IVUS examination was not possible. Therefore, only 
40 stents were eligible for the study. 
 
4.2 Patients’ Profile 
 
A total of 33 patients were enrolled in the study wherein a total of 39 lesions were 
treated with 40 stents. 
 
Out of the 11 patients for Group A, two stents were implanted for each of two patients: 
each with two separate lesions. One had five lesions, each lesion was treated with a 
stent. Therefore, 11 patients received 17 stents for 17 lesions. 
 
Of  the 22 patients in Group B,  only one had two stents for a long lesion. Therefore, 22 
patients received 23 stents for 22 lesions. 
 
Group B showed higher percentage of patients with hypertension, hypercholesterolemia, 
and higher serum creatinine level. An indication of poorer prognostic outcome for 
Group B but these had no clinical relevance according to statistical computations. 
Although Group A showed higher incidence of significant family history and history of 
previous myocardial infarction, it did not also reach to a significant level. See Table 1 
for their clinical characteristics.  
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Table 1. Clinical Profile: 
Characteristics of 
Patients (n=33)* 
Group A (11) Group B (22) 
Age 63±8y/o 63±11y/o 
BMI 45±5 50±8
Creatinine 1.1±0.2mg/dl 1.4±0.9mg/dl 
Women 36% 23% 
Smoker 41% 53% 
Diabetes 29% 24% 
Hypertension 65% 76% 
Hypercholesterolemia 53% 65% 
Family History 76% 12% 
Previous MI 65% 35% 
Revascularization 55% 55% 
* - p-value for all parameters was not significant. 
 
4.3 QCA Investigation 
 
By angiographic characteristics, the lesion type according to the American Heart 
Association and American College of Cardiology joint classification was an important 
parameter dictating the outcome of percutaneous coronary intervention. Group B 
showed predominance of lesion type B2 while Group A showed trending towards lesion 
type A and B1. Therefore, Group B had poorer prognostic lesion types which later 
translated to clinical significance; that is, lower success rate of stent deployment. The 
other angiographic measures such as minimum lumen diameter, percent diameter 
stenosis, and lesion length had no bearing to the resulting clinical picture since they 
revealed no significant statistical difference. See Table 2 for their angiographic features. 
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Table 2. Angiographic Profile: 
Characteristics of 
Lesions (n=39) 
Nominal Pressure Stent-
Implantation Group A 
(17) 
High Pressure Post-
Stent Dilatation Group 
B (22) 
p-value
MLD (mm) 0.96±0.21 0.95±0.36 ns 
Diameter Stenosis (%) 61±11 62±15 ns 
Reference Diameter 
(mm) 
2.60±0.55 2.58±0.44 ns 
Lesion Length (mm) 14.45±6.49 15.39±6.23 ns 
Lesion Type 
(ACC/AHA) 
A
B1 
B2 
C
4
7
4
2
0
4
15 
2
P<0.05
Target Vessel 
LAD 
LCX 
RCA 
 
4
4
9
3
10 
9
-
4.2 IVUS Investigation 
 
The minimum CSA and average CSA of the reference and stented segments were 
comparable for both groups. The vessel CSA was also comparable according to 
statistical computations. The difference was certainly seen in parameters between the 
stent implantation and post-dilatation phases of Group B. (p<0.05)  Therefore, the acute 
luminal gain was 1.29±0.84mm2 within the stented region. Refer to Table 3 for the 
luminal area parameters. 
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Table 3. IVUS Results: 
CSA Parameters 
(mm2)
Group A 
(15*) 
Group B1 (20**) 
( Stent Implantation)
Group B2 (23) 
(Post-Stent Dilatation)
p-value 
Min ref segment*** 5.58±2.36 6.72±2.55 - ns
Ave ref segment*** 7.67±3.80 9.01±3.18 - ns
Min in-stent 6.85±2.53 6.69±2.07 7.78±1.83 A vs B2, p=ns 
B1 vs B2, p<0.05 
Ave in-stent 8.12±2.89 8.13±1.80 9.35±1.96 A vs B2, p=ns 
B1 vs B2, p<0.05 
Ave vessel 17.06±6.90 17.04±4.61 17.70±4.42 A vs B2, p=ns 
B1 vs B2, p<0.05 
Delta in-stent**** - 1.29±0.84 -
Delta vessel**** - 0.93±0.98 -
* -Two stents of Group A were implanted adjacent to another one. They were then 
analyzed sonographically as one stent. 
** -Three stents of Group B were obviously not successfully implanted since the 
angiogram showed the balloons to have indentations at 9 atm. They were directly post-
dilated with higher pressures without undergoing IVUS. 
*** -Only the parameters at stent implantation were used throughout as reference. 
**** -Additional luminal area gain noted at post-stent dilatation compared with stent 
implantation of group B with significantly different parameters (p<0.05). No pre-
intervention IVUS was performed. 
 
The description for lesion calcification was performed after intervention. Although 
statistics did not prove it, a trend could be delineated wherein Group B had more severe 
calcification as indicated by a greater arc of calcium around the stent. Even the 
correlation coefficients, these apparently showed negative association; that is, the 
heavier calcification, the smaller the stented lumen. Refer to Table 4 for further 
scrutiny. 
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Table 4. Lesion Calcification by IVUS 
Entire Stented 
Segment 
All 
Lesions 
Group A Group B p-value
A vs B
Maximum arc of 
calcium in degrees
100±65° 97±74° 102±60° ns 
Correlation with 
minimum CSA* 
r = -0.11 r = 0.09 r = -0.34 ns 
Correlation with 
average CSA* 
r = -0.12 r = 0.07 r = -0.42 ns 
*- Pearson’s r correlation coefficient was used. 
All coefficients were not statistically significant. 
 
4.3 Optimum Stent Deployment Yield Analyses. 
 
By angiographic optimum stent deployment criteria of <10%, Group A had a better 
yield of 53% (9/17) than stent implantation parameters of Group B, 39% (9/23). But, 
Group B at post-stent dilatation drastically improved to 78% (18/23). This was a clear 
indication of the need for higher pressure postdilatation procedure. But, aggressiveness 
to achieve successful stent deployment entails arterial injury. The corresponding yield 
by Group B of 74% (17/23) at a balloon:artery ratio of >1.0 was expected. Refer to 
Table 5 for the angiographic analysis. 
 
It was the primary objective to assess by means of IVUS the optimal deployment 
pressure for the new generation ExpressTM Coronary Stent System. Based on the 
Modified MUSIC criteria, Group A & B had comparable success rate of 76% (13/17) 
and 70% (16/23), respectively. See Tables 5 for the  criteria yield analysis. Please refer 
back to section 2.3 to review optimum stent deployment criteria. 
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Table 5. Yield Analyses: 
Group B (23) Post-Interventional Analyses 
Total = 40 stents*** 
Group A 
(17) Nominal Pressure (B1) Post-Dilatation (B2)
a. Stent Symmetry(>0.7)* 82% (14) 91% (21) 96% (22) 
b. CSA Ratio 94% (16) 57% (13) 74% (17) 
c. Good Apposition 100% 96% (22) 100% 
IVUS 
Modified MUSIC Criteria** 76% (13) 48% (11) 70% (16) 
<10% Diameter Stenosis 53% (9) 39% (9) 78% (18) QCA 
Balloon:Artery >1.0 59% (10) 22% (5) 74% (17) 
* -ratio of minimum stent diameter with maximum lumen diameter 
** -fulfilled the three IVUS criteria as successful stent deployment 
*** -p-value for all parameters were not significant 
except for CSA Ratio, A vs B1, p<0.01 
 
4.4 Immediate Clinical Outcome 
 
The sonographic  and angiographic criteria of optimal stent implantation were achieved 
in more than half of each group. No myocardial or acute coronary occlusion occurred 
during the procedure. No major complications such as death, emergency coronary 
bypass surgery or cerebro-vascular events occurred during the procedure or clinical 
stay. 
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5. DISCUSSION 
5.1 Patients’ Appraisal 
5.1.1 Low-to-Moderate Risk Patient Selection  
 
The patients selected for the study involved not the high-risk population. This study 
focused only on procedural technique that reported only immediate surrogate endpoints. 
Although the study mentioned also the immediate clinical outcome during the patients’ 
hospital stay. Patients with chronic stable angina and significant de novo lesion were 
appropriate patients to be managed with newly designed bare stainless steel slotted 
tubular coronary stents. 
 
5.1.2 Small Sample Size 
 
Due to the small sample size of the study, only trending was appropriately used to 
describe the differences between the two unequal groups. The necessary robust non-
parametric tests were applied only when the pre-requisites for a student’s t-test were not 
met. Hypertension and hypercholesterolemia were major risk factors against Group B 
which could influence the outcome of PCI. The angiographic lesion type according to 
the ACC/AHA Lesion Classification System (p<0.05) was the break point that directly 
dictated the structural endpoint of PCI. From the mean parameters of IVUS, the average 
minimum in-stent CSA and overall in-stent CSA showed a wide margin between the 
two pressure groups. The lesion calcification severity measured by arc in degrees was 
the negative influence for Group B’s intervention outcome and inversely correlated with 
their luminal dimensions. Describing by percentage distribution was the best option to 
discuss analyses of optimum stent criteria. The largest effect of high pressure technique 
was observed with Group B’s cross-sectional area of their stent lumen. (p<0.05) 
 
5.1.3 Patient’s Assignment to Groups 
 
The study utilized a stepwise procedural selection of patients for assignment of groups 
dependent on immediate visualized results of intervention. The patients were enrolled 
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consecutively who have received the EXPRESS™ Coronary Stent System as the stent 
used for PCI. Randomization for assignment of groups would be unethical and immoral. 
When patients would be assigned fixed to the nominal pressure group and their stents 
were only suboptimally expanded or underexpanded, these subset of patients would be 
predisposed to subacute thrombosis.23-27 
 
5.1.4 High Pressure Post-dilatation Group as Control 
 
Since the study was started at that time when the high pressure strategy was already 
recommended by the American College of Cardiology Expert Consensus Document on 
Coronary Artery Stents, the high pressure group would be appropriately assigned as the 
control group. The new generation Express coronary stent system was believed to be 
recently developed to employ only nominal pressure enough to optimally expand the 
stent into a coronary lesion. Newly designed stents were still being developed since the 
recommended high pressure technique was believed to create more arterial injury that 
would translate to greater restenosis.32-44 Once the MUSIC criteria had been met, the 
stent was classified as “successfully deployed” even though post-dilatation procedure 
could enlarge further the stent lumen area. The policy “the bigger, the better” was not 
carried out as a protocol in this study.14,15 
5.1.5 Low or Nominal Balloon Inflation Pressure Proponents 
 
Di Mario mentioned that high pressure strategy was already obsolete and unnecessary 
with the modern pre-mounted second and third generation stents.32 These newly-
designed stents were mechanically crimped on dedicated balloons and could be evenly 
expanded at low pressures. On the other hand, they had to overcome the resistance to 
expansion of severe calcified plaques. But the CONSERVE trial did not prove that 
newly designed stents like the LP stent can be fully expanded by low inflation 
pressure.76 Takano’s study also revealed that the mean minimum stent CSA of 38 new 
generation stents in 32 patients achieved only 62% of the manufacturer’s expected stent 
area despite moderately high-pressure inflations of 14-16 atm.77 
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But, an exceptionally good long-term clinical outcome defined by a low rate of clinical 
events supports the theory that low restenosis rate and secondary good long-term 
clinical outcome could be achieved when adequate stent deployment was effected by the 
use of low pressure inflation. This was supported by several studies including that of  
Cafri.37,38,78,79 61% of  stented lesions fulfilled the IVUS criteria of appropriate stent 
deployment using only low inflation pressure of 10 atmospheres was seen in 
Hoffmann’s study.80 
 
5.2 Procedural Appraisal 
5.2.1 Exactness of Inflation Pressure Range 
 
A clear-cut definition of high pressure should be described. The American College of 
Cardiology Expert Consensus Document on Coronary Artery Stents recommended ≥12-
16 atm to be used as high-pressure inflation.28 This was the pressure range used also by 
the proponents.20,21 
In our study, there were deviations from the pre-defined pressure range in both groups. 
A cross-over of individualized inflation pressures probably indicated that a standard 
protocol can not be applied to all kinds of lesions. Dirschinger also deviated from the 
study protocol to individualize lesion management.81 
 
Other studies used higher pressure of ≥16 atm.82-87 Schatz tried to define the low 
pressure range using 6-10 atm23 or 9-12 atm.88 Before the advent of the high-pressure 
technique, the BENESTENT trial used a mean of 10±8 atm.89 Several studies support 
that low-pressure deployment as low as less than 9 atm is associated with higher rate of 
adverse events. Cafri used an average inflation pressure of 8.0 atm which was 
associated with higher frequency of stent thrombosis (6.6%) with subsequent adverse 
clinical events despite the routine utilization of ticlopidine –aspirin treatment.78 Similar 
rates of stent thrombosis were observed by Karrillon who used less than 8 atm showing 
4.9% incidence.90 Goldberg reported 4.4% event rate using 9 atm.91 Sick, in his recent 
comparative analysis of AVE microstents with low and high pressure approach, showed 
higher sub-acute thrombosis rate in a group with mean pressure of 8.8 atm.92 Therefore, 
a low inflation pressure for stent implantation should not be routinely used. Sometimes 
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neointimal proliferation was not related to stent implantation aggressiveness, rather it 
was directly related to plaque lesion characteristics dictating modifications in stent 
implantation pressures. This was supported by studies giving importance to lesion 
plaque burden as a predictor for subsequent tissue proliferation with greater lesion 
plaque burden requiring greater stent implantation forces.  
 
5.2.2 Diversified Interpretation of Optimization of Stent Deployment 
 
Hanekamp used also myocardial fractional flow reserve as one of the modalities to 
evaluate optimum stent deployment as compared with other evaluation modalities. A 
graph showed the cumulative distribution of observations with optimum stent 
deployment according to different evaluation modalities in relation to increasing 
inflation pressure. For the Wiktor-I stent in the study, the inflation pressures necessary 
to obtain optimum stent deployment as assessed by IVUS are higher than the equivalent 
pressures needed as assessed by QCA alone. During the step-up of pressures, a total of 
81 paired IVUS and FFR measurements were performed, of which 91% yielded 
concordant results. Optimum stent deployment according to IVUS or FFR was always 
achieved only in 60% of cases. Refer to Figure 9.93 
Figure 9. Graph depicted that even with high pressure strategy, 
only 60% of the patients could achieve optimum stent 
deployment based on IVUS and FFR. 
 
Page  31
Ludwig-Maximilians-Universität 
Moussa maximized the use of IVUS in determining the optimum deployment criteria. 
Out of five IVUS criteria, the protocol with 55% ratio between in-stent mimimal lumen 
CSA and average reference vessel CSA showed the lowest incidence of restenosis. He 
emphasized that IVUS was the best guide to stent implantation. Useful information 
provided by IVUS to be considered by the operator were appropriate balloon upsizing, 
and  the media-to-media diameter for target lumen gain.50 
The modified MUSIC criteria for optimum stent deployment should be observed during 
PCI since it had reported to have the lowest restenosis rate of 10%. Refer to Figure 10. 
Both two groups met the criteria similar to the MUSIC trial of 81%.94,95 
Figure 10. The linear curve revealed that the average MLD 
was  inversely related to restenosis rate. The MUSIC trial 
was effective in obtaining larger luminal dimensions 
translating to better long-term outcome. 
 
5.2.3 Effect of  Pre-Dilatation 
 
Stent implantation preceded by predilatation already meant almost 100% 
circumferential endothelial denudation. But, partial retention of endothelium in case of 
primary stent implantation was associated with reduced mural thrombosis, inflammation 
and subsequent neointimal hyperplasia. So, Hoffman’s study on different deployment 
pressures might had obscured the results for stent-induced vascular injury due to pre-
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dilatation of the lesion.70,96 Similar consequence should also be considered in our study 
since majority of our patients were pre-dilated prior to stenting. 
 
5. 2.4 Improvement in Stent Designs 
 
For tubular-slotted designed stents such as Palmaz-Schatz stents, high-pressure 
adjunctive balloon dilatation at 16 atm or higher pressures became a routine practice. 
The Palmaz-Schatz stents showed complete stent expansion and apposition to the vessel 
wall minimizing thrombogenicity without using systemic anticoagulation.57,64,97 
Dirschinger  used slotted-tube stents of five different types and showed more favourable 
acute angiographic results at 30-days follow-up from high-pressure implantation.81 
High-pressure balloon dilatation seemed necessary for first-generation balloon 
expandable stents due to their design limitations.21,57 These design limitations included 
reduced axial flexibility (slotted tubular design), poor trackability through tortuous 
anatomy, inadequate scaffoldings (coiled designs), limited size range (lengths and 
diameters), and suboptimal radiopacity. To compensate for these shortcomings, 
modifications in the material, geometry, and surface coverage of stents were 
incorporated into the second-generation stents, which provided high radial strength, 
excellent longitudinal flexibility, and better vessel scaffolding. But, inspite of these, 
most stents still had low yield for optimum deployment due to the semi-compliant 
balloon material of the stent delivery system.98 
 
Caixeta tried  another  stent design using MultiLink Stents for implantation pressure 
comparison. These were balloon expandable stainless-steel stent with interconnected 
corrugated rings structure model. At first, it was not advised to dilate it with high 
pressure because it could be deformed without really offering any clinical benefits or 
exhibiting better luminal dimensions than nominal pressures.99-101 Kalmar used the same 
stent between 9 and 15 atm since beyond 15 atm, very minimal lumen gain was 
attained.48 
The Austrian Wiktor Stent Study Group utilized their uniquely designed stent, a single-
wire tantalum coil stent, for conventional low pressure deployment and high pressure 
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post-dilatation. Their study demonstrated favourable short- and long-term results with a 
trend towards additional lumen gain by high-pressure post-dilatation. But, this did not 
translate into measurable improvement in long-term outcome.102 
On the other hand, Caixeta demonstrated a greater acute gain with high pressure 
strategy. This was supported by other reports based on QCA and IVUS, even with 
favourable early clinical outcome.101,103-105 
The new generation EXPRESS™ Coronary Stent System was recently developed to solve 
the problem of acute vascular injury aggravated by high pressure technique. This was a 
slotted tubular stainless steel with a new geometric mesh design. It had Tandem 
Architecture™ technology, which had combined Micro and Macro elements for a high 
degree of vessel support, and consistent radial strength.71 See Figure 11. 
 
Figure 11. This stent design demonstrated the 
Tandem Architecture™ technology. 
 
Recently, the same stent was developed into Taxus, a slow-release, polymer-based, 
paclitaxel-eluting stent to reduce the risk of restenosis after the treatment of short, focal 
atherosclerotic lesions in humans. Paclitaxel is a lipophilic substance that came from the 
Pacific yew tree Taxus brevifolia and inhibited cellular processes of reproduction, 
motility, activation, secretory processes, and signal transduction. In vitro and in vivo 
studies demonstrated its effectiveness in reducing neointimal hyperplasia after balloon- 
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and stent-mediated injury. It became a slow-release, polymer-based, paclitaxel-eluting 
stent to reduce the risk of restenosis after the treatment of short, focal atherosclerotic 
lesions in humans had been demonstrated in small-to-moderate-sized studies.106 
5.2.5 Improvement in Balloon Material 
 
Improvement of balloon characteristics encouraged the use of high pressure. Modern 
balloons with pre-mounted stents had a rated burst pressure of at least 14-18 
atmospheres and grow predictably when high inflation pressures were used. Focal 
balloon technology, precise matching of balloon and stent length with very short 
balloon shoulders, balloon materials ensuring low predictable compliances, and evenly 
distributed diameter changes along the balloon length (no dog-bone effect) had made 
high-pressure stent implantation a technique easier to apply and less prone to procedural 
complications.32 
 
The opposing effect of high pressure strategy between large post-procedural luminal 
dimensions and subsequent arterial injury might be resolved by the use of less 
compliant balloons to release consistent high pressure on the stent struts without 
increased balloon to artery surface contact stress during implantation.107 
 
The early-generation balloon-expandable stents used for PCI were delivered with 
compliant balloons that required postdilatation with noncompliant balloons at high 
pressure to optimize stent deployment.21,94,98,108 In the Angiography Versus 
Intravascular Ultrasound-Directed Stent Placement (AVID) Study, 57% of patients 
achieved optimum stent deployment criteria after postdilatation with high pressure 
balloons.109 IVUS-guided, high-pressure balloon inflations provided larger minimal 
stent area which translated into better long-term outcome.64,98 
But, Roberts proved that the non-compliant nature of balloons for postdilatation which 
were of the same size and inflated to the same pressure as the current semi-compliant 
stent deployment balloons was responsible for stent expansion.110 
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There was no uniform balloon used in our study for post-dilatation procedure which 
could had worsened  the real effects of high pressure stent deployment. 
 
But, the EXPRESS™ Coronary Stent System used the DynaLeap™ balloon material 
which was characterized by minimal overhang and predictable and controlled balloon 
growth sizing. These features promoted precise stent dilatation and offered the right 
combination of softness and low profile.71 See Figure 12. 
Figure 12. This special balloon material, DynaLeap™, was semi-compliant 
but displayed predictable and controlled balloon dilatation 
 
5.2.6 Anti-thrombotics and anti-coagulants 
 
The high-pressure strategy coincided with the emergence of ticlopidine plus aspirin  as a 
post-stenting therapy. The advantage of combined anti-platelet therapy over 
anticoagulation for the prevention of stent thrombosis might had boost the positive 
effect of high-pressure technique on restenosis. Since it also improved flow 
characteristics, the independent role of Colombo’s idea should be clarified.82,111-115 
Dirschinger showed no significant difference between the low and high pressure groups 
in terms of complications.81 Mattos showed also no improvement in late outcome.116 
The reported range of stent thrombosis was similar for patients treated with combined 
anti-platelet agents after stenting.21,22,90,117 
Anti-thrombotic regimen was still maintained on all our patients after PCI. 
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5.2.7 Comparison with Other Studies 
 
Hoffman used similar low to moderate risk subset (symptomatic one-vessel coronary 
artery disease) but with a bigger population (120) using also a new generation stent, 
Multi-Link HP stent. Randomization was performed after which they described 
separately that subset from the low pressure group that required additional 
postdilatations. Low pressure stent implantation was found to be inadequate even with 
the new generation stent. High-pressure technique did not cause more significant 
neointimal proliferation and the resulting larger luminal parameters were maintained on 
follow-up.47 
Dirschinger excluded also high-risk patients in their study using various stainless steel 
stents with new multicellular designs. A successful stent deployment only defined 
angiographically as a diameter stenosis of less than 30% was a very lenient rule. Thirty-
day and one-year outcome assessments were included in their protocol. One –year 
outcome did not show any advantage of high-pressure strategy.81 
Cafri’s retrospective study of 90 consecutive patients using AVE microstent used only 
low pressure inflation. Oversizing of stent or balloon was utilized obtaining a vessel 
ratio of 1:1. No control group (high pressure) was included for comparison. Again, the 
angiographic success was defined loosely at less than 30% diameter stenosis. No IVUS 
was used. Complete stent expansion on both pressure strategies indicated long term 
benefits, together with aggressive anti-platelet regimens. But, low pressure technique 
should be selectively performed deriving also benefits from lesser degree of vessel 
trauma.78 
Caixeta’s study indicated consecutive collection of patients with the first half having 
low pressure balloon inflation (<16 atm) and then the second half having high pressure 
technique. (>16 atm) Multilink stents were used observing only angiographic and 
clinical outcome until six-months follow-up. No randomization was done. The patient 
with transmural myocardial infarction was excluded from the study. They only counted 
in all successful cases for evaluation. Only a trend was seen at six-month follow-up 
wherein the high pressure group had lower restenosis.49 
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The Austrian Wiktor stent study group conducted a prospective randomized multicenter 
trial using QCA and IVUS to describe result parameters. No criteria was observed for 
optimum stent deployment. Short and long term outcome were gauged through loss 
indices of restenosis and clinical hard endpoints. No difference in outcome was seen 
between the two groups. But, low incidence of adverse events and target lesion 
restenosis were observed with the use of single-strand helical coiled tantalum Wiktor 
stent.118 
Görge characterized the differences in IVUS between the two pressure groups using 
Palmaz-Schatz stents. This was not randomized and was performed as an emergency 
procedure. The IVUS criteria for successful deployment used stent symmetry, MLD, 
stent apposition with luminal wall and absence of residual dissection as parameters. 
Optimal stent expansion was not observed in all patients with high pressure strategy.57 
5.3 Results’ Appraisal 
5.3.1 Effect of Lesion Calcification on Stenting 
 
The high pressure group was also evaluated by QCA and IVUS during the nominal 
pressure stent implantation phase for intra-group comparison of parameters. An 
important observation in this study was the subset of  patients with stents not fully 
expanded during the nominal pressure stent implantation phase remained suboptimally 
expanded even on repeated high pressure post-dilatation. Further scrutiny of these 
patients revealed that they had the worst lesion types, together with heavy calcification. 
 
Vavuranakis demonstrated that the calcium factor in atherosclerotic plaques could not 
be completely eliminated by high pressure strategy. Increase in stent lumen area was 
achieved with this technique in moderate to severely calcified lesions but with poor 
lumen symmetry which was probably due to vessel overexpansion at the non-calcified 
segments.119 
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5.3.2 Balloon Sub-expansion and Acute Elastic Recoil 
 
Aside from calcification as the probable cause, Bermejo elaborated also on two other 
possible mechanisms of residual lumen stenosis: balloon subexpansion and elastic 
recoil. Balloon sub-expansion was defined angiographically by the ratio of minimum 
balloon diameter with maximum balloon diameter.120 
 
Balloon sub-expansion could result from interference of stent architecture. A study 
showed that Palmaz-Schatz stents expand by almost 90% reaching 5 atmospheres. 
Beyond this limit, it was believed that no significant increase in pressure would be able 
to fully expand  this balloon-stent assembly.121 Greater compliance  of balloons could 
also be partly responsible for such defect. This was clearly observed with the Wiktor 
stents after implantation.120 
Immediate reduction of the vessel lumen sometimes occurred immediately after balloon 
deflation accounting for approximately 50% loss in acute lumen gain during PTCA. 
This was called acute elastic recoil.122-124 With the use of stents, recoil had narrowed 
only the lumen CSA to 20%.119 Studies of  Wiktor and Palmaz-Schatz  stents showed 
12% loss angiographically.62,63,125-130Another mechanism of lumen recoil was plaque 
protrusion through the stent struts because of its small metallic surface. This could be 
easily seen by IVUS and angioscopy.131-133 
Carrozza showed that the acute elastic recoil was greater for coiled stents (30%) while 
that of slotted-tube stents is only half.(15-17%) The effect of acute elastic recoil was 
clearly demonstrated in this animal study with the use of a special IVUS imaging core 
inserted within the inflated balloon. This finding was also observed by Bermejo120 and 
Werner133. Therefore, to achieve a final stent-to-artery ratio of 1.0, the coiled stents 
would need to be over-expanded to a balloon-to-artery area ratio of 1.4 (diameter ratio 
of 1.2), whereas slotted-tube stents should had an area ratio of 1.2 (diameter ratio of 
1.1).134 
Improvement of balloon-vessel matching might reduce residual lumen stenosis after 
stenting. This could be possible only with the use of IVUS as can be seen from the good 
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results of standard PTCA procedure.135 The plaque responsible for subexpansion and 
recoil was best illustrated by IVUS.136 Therefore, a customized deployment technique 
could be performed. 
 
Another way of increasing luminal dimensions was by debulking before stenting 
because it modified vessel impedance.136-138 
5.3.3 Deviation from Expected Outcome 
 
The angiographic and sonographic results in the high pressure group after post-
dilatation were as expected which were within the range of successful deployment 
percentage of 60-80%.20 
But, the sonographic results of Group A were higher than expected since only nominal 
pressure was used. The only possible mechanisms that could lead to such good 
surrogate endpoints was the characteristics of the patients in Group A. Their clinical 
profile indicated mild to moderate risk for acute coronary syndrome. The prominent 
milder angiographic lesion type (p<0.05) including also milder lesion calcification 
severity by measure of circumferential calcium could have brought about the favourable 
outcome of PCI. 
 
5.3.4 Discrepancy Between Two Imaging Modalities 
 
Another point of argument was the discrepancy between angiographic and sonographic 
yield of optimum stent deployment criteria. Blasini compared both imaging modalities 
in relation to varying dilation pressures. Findings showed that on low pressure dilation, 
relying solely on intra-stent MLD by QCA will not yield accurate information. But, 
after high pressure dilation, the difference between IVUS and QCA was minimized. The 
possible explanation was that IVUS can detect the contact of the nearly radiolucent but 
highly echographic struts with the vessel wall and their shape as the endoluminal 
outline. On the other hand, the outline of the vessel wall between the stent struts 
consisted the demarcation line for endoluminal diameter. In other words, the QCA 
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detected only the irregularly shaped plaque formation to determine intra-stent 
MLD.139,140 
5.3.5 Definition of Structural Ratios Affecting Vessel Injury 
 
In this study, only the balloon:artery ratio was defined angiographically to depict acute 
injury score. But, other investigators had their own preference to relate to injury. 
Carroza used a special imaging core wire entered through the guide wire lumen of the 
balloon catheter to measure the actual balloon dilatation. Thus, a more accurate 
measurement of balloon:artery ratio was achieved. Another group has simply used the 
manufacturer’s product specification to define stent:artery ratio.134 
 
5.4 Limitations of the study 
 
Since the study was conducted on a stepwise procedure with assignment to groups 
depending on the initial deployment outcome, randomization of patients to assigned 
groups would had removed selection biases. On ethical grounds, additional dilatation to 
the nominal pressure group should be performed on inadequately expanded stents, they 
then belong to a special subset of the nominal group requiring a separate scrutiny.    
 
Like the study of Blasini, IVUS was performed only after stent deployment. Thus, the 
IVUS assessment of plaque burden and morphology was limited due to the metallic 
stent struts covering the plaque region. A detailed qualitative plaque analysis was not 
possible. The impact of plaque morphology on stent expansion was inconclusive.139  
But, superficial assessment of severity of calcification was possibly measured by 
degrees in circumferential arc since the EXPRESS™ Coronary Stent System allowed 
clear visualization of structures behind the struts despite its echogenicity. 
 
The study dealt only with immediate procedural outcome of PCI with particular 
emphasis on compliance to optimum stent deployment criteria based on IVUS and 
QCA. Results would be more dramatic when in-stent restenoses could be monitored on 
a six-months follow-up. Furthermore, long-term clinical hard endpoints such as 
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mortality and clinical vascular events could also be reported to correlate with procedural 
objectives. 
 
Small sample size could have affected the true outcome of the study. Trending was the 
only alternative to describe results whenever statistical tools utilized did not provide 
adequate level of significance.   
 
5.5 Summary of Discussion 
 
Because of the deleterious vascular injury and resulting restenosis from high pressure 
post-dilatation strategy, the EXPRESS™ Coronary Stent System was recently developed 
with its new features: the Tandem Architecture™ technological design and DynaLeap™ 
balloon material. With its new characteristics, nominal pressure was supposed to be 
enough to achieve optimum stent implantation. The high pressure post-dilatation group 
became the control group. The modified MUSIC criteria was used because its yield 
translates into 10% restenosis. Unfortunately, this study examined only immediate 
procedural outcome. Most studies observed also short and long-term outcomes. 
Assignment of patients to groups was dependent on procedural outcome and operator’s 
discretion. Since randomization was not carried out, the high pressure post-dilatation 
group had poorer prognostic outcome due to its worse AHA/ACC lesion type (p<0.05) 
and tendency to have more severe lesion calcification. Due to its small sample size of 
low-to-moderate risk patients, trending could only be described from most of the 
results. As seen in other investigations, a few cross-over of pressure ranges was carried 
out due the operator’s discretion applying the appropriate pressure for different sorts of 
lesions. Discrepancy in interpretation between QCA and IVUS was observed  resulting 
from inaccuracies in the automatic border detection of the QCA software after low 
pressure stent implantation. Several studies showed also similar QCA and IVUS yield 
of optimized criteria of 60-80% including the discrepancy in their interpretations. 
Calcification, balloon sub-expansion and acute elastic recoil were the possible 
mechanisms responsible for failed stent deployment. Pre-dilatation meant almost 
complete circumferential endothelial denudation which might had distorted out results.   
Anti-thrombotics and anti-coagulants should always complement the stenting 
procedure.  
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6. CONCLUSION 
 
Based on QCA and IVUS optimum stent deployment criteria, the nominal pressure stent 
implantation parameters of Group A were comparable with the high pressure post-
dilatation parameters of Group B. But, the non-randomized procedural outcome 
assignment protocol of patients probably predisposed Group B to poorer prognosis due 
to its worse AHA/ACC lesion type and tendency to heavier lesion calcification. The 
inaccurate automatic vessel border detection may have obscured the nominal pressure 
results leading to discrepancies between the two imaging modalities. 
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7. SUMMARY 
 
Despite being recommended by the American College of Cardiology Expert Consensus 
Document on Coronary Artery Stents, high pressure post-dilatation strategy still 
encountered several controversies due to its deleterious effects on the vascular wall and 
its distortion of the stent geometry leading to a predilection to restenosis. Researches 
were geared to the development of newly designed coronary stent systems to be 
deployed at low pressure minimizing vessel trauma. In this study, the EXPRESS™
Coronary Stent System underwent scrutiny based on QCA and IVUS comparing both 
nominal and high balloon inflation pressures. 
 
IVUS and selective coronary angiography  were performed after initial stent 
deployment at 9 atmospheres and after post-stent dilatation up to as high as 20 
atmospheres. If stent deployment was not perceived to be optimal, stent was dilated 
once to three times and post-stent balloon inflation pressure could be increased at the 
discretion of the investigator until perceived to be optimally expanded according to the 
Modified “MUSIC” criteria. 
 
Stents implanted at nominal pressure and perceived to be already successfully deployed 
sonographically and angiographically belonged to Group A (n=17). No high-pressure 
post-stent dilatation was required. 
 
Stents implanted at nominal pressure and perceived to be not optimal by angiography 
with or without IVUS were further dilated with higher balloon pressure inflations until 
perceived to be successfully deployed based on angiography and IVUS. These belonged 
to Group B (n=23). 
 
Pre-dilatation was performed on both groups once to three times when perceived to be 
necessary. The routine protocol for anti-thrombotics and anti-coagulants was also 
followed. 
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The immediate outcome of PCI from both groups were comparable. However, the high 
pressure group had poorer AHA/ACC lesion type and heavier lesion calcification. This 
could had prevented achieving  a much higher  yield of successful stent deployment. 
The inaccurate QCA interpretation at low pressures could have explained the apparent 
disagreement between the two imaging modalities. 
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8. ZUSAMMENFASSUNG 
 
Obwohl die Dilatation unter Hochdruck durch die American College of Cardiology 
Expert Consensus Document on Coronary Artery Stents empfohlen wird, gibt es noch 
einige Kontroversen bezüglich der möglicherweisen schädigenden Effekte auf die 
Gefäßwand sowie die Verzerrung der Stentgeometrie. Beides führt zu einem erhöhten 
Restenoserisiko. Um eben dieses Risiko zu minimieren, werden derzeit 
Niederdrucksysteme erforscht. In der vorliegenden Studie wurde das EXPRESS™
Coronary Stent System unter nominaler und hoher Balloninflatation mittels QCA und 
IVUS verglichen. QCA wurden nach Stentexpansion zunächst bis 9 atm sowie 
Hochdruckdilatation bis zu 20 atm durchgeführt. Wenn die Stentexpansion dabei nicht 
optimal war, konnte der Stent ein- bis dreimal erweitert werden und der 
Balloninflatationsdruck nach Einchätzung des durchführenden Arztes (Katheteriseurs) 
erhöht werden, um entsprechend den modifizierten „MUSIC“ kriterien optimiert zu 
werden. 
 
Stents, die nach IVUS and QCA Beurteilung bereits mit nominalem Druck optimal 
implantiert waren, gehöhrten der Gruppe A (n=17) an. Eine Hochdruckdilatation nach 
Dehnung war hier nicht erforderlich. 
 
Stents, die mit nominalem Druck implantiert wurden und nach IVUS bzw. QCA- 
Kontrolle nicht optimal waren, wurden noch einmal mit Hochdruckinflatation entfaltet 
bis das Ergebnis basierend auf IVUS und QCA optimal war (Gruppe B, u = 23). 
 
Eine Prädilatation wurde an beiden Gruppen ein- bis zu dreimal durchgeführt, je nach 
Notwendigkeit. Das Routineprotokoll für antithrombotische und antikoagulatorische 
Medikation wurde eingehalten. Das sofortige Resultat von PCI war bei beiden Gruppen 
ähnlich. Die Hochdruckgruppe zeigte jedoch schlechtere Koronarläsiontypen nach 
AHA/ACC und schwere Gefäßkalkbildung. Dies könnte ein Grund für die niedrigere 
Anzahl erfolgreicher Stentexpansionen sein. Die ungenaue QCA Interpretation bei 
Niedrigdruckdilatation könnte die schlechte Korrelation zwischen QCA und IVUS 
erklären. 
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9. APPENDICES 
Appendix A. Classification of Lesion Type 
 Lesion Classification 
According to Standard 
American Heart Association/ 
American College of Cardiology 
Grading System 
Type A 
Discrete 
Concentric 
Readily accessible 
Non-angulated segment 
Smooth contour 
Little or no calcification 
Non-ostial 
No major side branch involved 
Absence of thrombus 
Type B 
Tubular 
Eccentric 
Moderate tortuosity 
Moderately angulated segment 
(45°–90°) 
Irregular contour 
Moderate-heavy calcification 
Total occlusion, 3 months
duration 
Ostial in location 
Bifurcation lesion 
Some thrombus present 
Type C 
Diffuse 
Excessive tortuosity 
Extremely angulated segment 
Total occlusion, 3 months 
duration 
Inability to protect major side 
branch 
Degenerated vein graft lesion 
B1 lesions consist of 1 B 
characteristic and B2 lesions 
consist of  ≥2 B
characteristics. 
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Appendix B. Classification of Angina 
 
Grading of Angina Pectoris by the 
Canadian Cardiovascular Society 
Classification System 
Class I 
Ordinary physical activity does not 
cause angina, such as walking, 
climbing stairs. Angina occurs with 
strenuous, rapid or prolonged 
exertion at work or recreation. 
Class II 
Slight limitation of ordinary activity. 
Angina occurs on walking or 
climbing stairs rapidly, walking 
uphill, walking or stair climbing after 
meals, or in cold, or in wind, or under 
emotional stress, or only during the 
few hours after awakening. Angina 
occurs on walking more than two 
blocks on the level and climbing 
more than one flight of ordinary 
stairs at a normal pace and in normal 
condition. 
Class III 
Marked limitations of ordinary 
physical activity. Angina occurs on 
walking one to two blocks on the 
level and climbing one flight of stairs 
in normal condition and at a normal 
pace. 
Class IV 
Inability to carry on any physical 
activity without discomfort—anginal 
symptoms may be present at rest. 
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